| 1.37 -0.05 (-3.52%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.73  |
1-year : | 8.36 |
| Resists | First : | 4.91 |
Second : | 7.15 |
| Pivot price | 2.48 |
|||
| Supports | First : | 1.26 | Second : | 1.05 |
| MAs | MA(5) : | 1.42 |
MA(20) : | 3.22 |
| MA(100) : | 7.93 |
MA(250) : | 57.15 |
|
| MACD | MACD : | -1.5  |
Signal : | -1.4 |
| %K %D | K(14,3) : | 2.9 |
D(3) : | 3.1 |
| RSI | RSI(14): 11.5 |
|||
| 52-week | High : | 416 | Low : | 1.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ALLR ] has closed above bottom band by 27.4%. Bollinger Bands are 90.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.47 |
| Low: | 1.34 - 1.35 | 1.35 - 1.36 |
| Close: | 1.36 - 1.37 | 1.37 - 1.38 |
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Wed, 17 Apr 2024
Allarity Therapeutics receives Nasdaq-approved extension to regain compliance - Seeking Alpha
Wed, 17 Apr 2024
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b ... - Yahoo Finance
Fri, 12 Apr 2024
Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today? - InvestorPlace
Fri, 05 Apr 2024
Allarity Therapeutics Announces Upcoming Reverse Stock Split - TipRanks.com - TipRanks
Thu, 04 Apr 2024
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split - GlobeNewswire
Tue, 26 Mar 2024
Allarity Therapeutics Granted Extension for Nasdaq Compliance - TipRanks.com - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 25 (K) |
| Shares Short P.Month | 33 (K) |
| EPS | -205.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -15.27 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -81.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.77 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|